- Cutting edge: novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathway. Westwood, J.A., Kelly, J.M., Tanner, J.E., Kershaw, M.H., Smyth, M.J., Hayakawa, Y. J. Immunol. (2004)